Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal

被引：57

作者：

Evans C. ^{[1
]}

Tavakoli M. ^{[2
]}

Crawford B. ^{[1
,3
]}

机构：

[1] Mapi Values, Boston, MA 02108

[2] University of St. Andrews, The Scores, St. Andrews, Fife KY16 9AL, St. Katherine's West

来源：

Health Care Management Science | 2004年 / 7卷 / 1期

关键词：

Benchmarks; Cost benefit; Economic evaluation; Methodology;

D O I：

10.1023/B:HCMS.0000005397.93173.bb

中图分类号：

学科分类号：

摘要：

Researchers have grappled with various ways of placing the results of an economic evaluation in the appropriate context. One of the most common methods is to relate the results of a study to an appropriate benchmark (commonly, $50,000 per QALY in the US or £30,000 per QALY in the UK). This paper examines the foundation for these cut-off points and critiques their use by researchers. Although it is difficult to establish an appropriate benchmark this paper notes that reference points may be too low based on published data. Further, the inconsistent application of benchmarks, and differences in the calculation of a value of a statistical life, will lead to an inefficient allocation of health care resources.

引用

页码：43 / 49

页数：6

共 42 条

[1]

Siegel J., Russel L., Weinstein M., Reporting cost effectiveness studies and results, Cost-Effectiveness in Health and Medicine, (1996)

[2]

Gafni A., Birch S., NICE methodological guidelines and decision making in the National Health Services in England and Wales, Pharmacoeconomics, 21, pp. 149-157, (2003)

[3]

Weinstein H.C., Stason W.B., Foundation of cost-effectiveness analysis for health and medical practices, New England Journal of Medicine, 296, pp. 716-721, (1977)

[4]

Drummond M.F., Torrance G.W., Mason J.M., Cost-effectiveness league tables: More harm than good?, Social Science and Medicine, 37, pp. 33-40, (1993)

[5]

Drummond M.F., O'Brien B., Stoddart G.L., Torrance G.W., Methods for Economic Evaluation of Health Care Programmes, (2000)

[6]

Duru G., Muray J.P., Beresniak A., Lamure M., Paine A., Nicoloyannis N., Limitations of the methods used for calculating quality-adjusted life-year values, PharmacoEconomics, 20, pp. 463-473, (2002)

[7]

Gafni A., Birch S., Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem, Canadian Medical Association Journal, 148, pp. 913-917, (1993)

[8]

Nord E., Health state values from multiattribute utility instruments need correction, Ann. Med., 33, pp. 371-374, (2001)

[9]

Nord E., Pinto J.L., Richardson J., Menzel P., Ubel P., Incorporating societal concerns for fairness in numerical valuations of health programmes, Health Economics, 8, pp. 25-39, (1999)

[10]

Williams A., Economics of coronary artery bypass grafting, British Medical Journal, 291, pp. 326-329, (1985)

← 1 2 3 4 5 →